Sox6 belongs to the Sry-related HMG-box family of transcription factors, which control cell fate specification of many cell types. Here we explore the role of Sox6 in human erythropoiesis by its overexpression in both the erythroleukemic K562 cell line and in primary erythroid cultures from human cord blood CD34 + cells. Sox6 induces significant erythroid differentiation in both models: K562 cells undergo hemoglobinization and, despite their leukemic origin, die within 9 days after transduction; primary erythroid cultures accelerate their kinetics of erythroid maturation and increase the number of cells reaching the final enucleation step. Searching for direct Sox6 targets, we found SOCS3 (Suppressor of Cytokine signalling-3), a known mediator of cytokine response.
INTRODUCTION
Sox proteins are important transcriptional regulators of different developmental processes where they control the specification and differentiation of many cell types. [1] [2] [3] In particular, Sox6, originally isolated form adult mouse testis 4 , is required for the development of the central nervous system [5] [6] [7] , for chondrogenesis 8 , and for cardiac and skeletal muscle formation. 9, 10 Recently, Sox6 has been demonstrated to be crucial for definitive erythropoiesis, [11] [12] [13] [14] [15] a process in which committed progenitors progressively differentiate into BFU-E and CFU-E, that in turn, give rise to proerythroblasts, erythroblasts and finally to mature, enucleated red blood cells (RBCs). These differentiation stages are accompanied by profound maturational changes: within few cell divisions, in parallel with the accumulation of erythroid-specific markers (membrane proteins, enzymes required for the heme biosynthesis pathway, globins), cells undergo chromatin condensation and enucleate. 16, 17 This complex spectrum of maturational steps is controlled, at the molecular level, by the integration of extrinsic (growth factors, oxygen and iron availability) and intrinsic (growth factor receptors, signalling mediators, transcription factors) signals.
Several transcription factors are essential for erythroid commitment and for differential globin genes expression during development: their absence is associated with a wide spectrum of phenotypes ranging from mild perturbation to death due to a complete failure of erythropoiesis. 18, 19 Among them, Sox6 has been recently shown to stimulate erythroid cell survival, proliferation and terminal maturation during definitive murine erythropoiesis. 11, 12 Sox6-null mouse fetuses and pups are anemic and present defective RBCs. Sox6 has recently been implicated in the silencing of embryonic globins genes: it directly silences the embryonic εy-globin gene in definitive erythroid cells by binding to the εy promoter 13, 14 and it cooperates with BCL11A in silencing γ-globin expression, possibly via direct physical interaction. 15 Here we show that Sox6 overexpression in K562 and in primary erythroid cultures from cord blood derived-CD34 + cells induces enhanced erythroid differentiation in both models. In K562 cells, differentiation is associated with reduced proliferation, leading the culture to exhaustion within 9 days after transduction. Accordingly to the phenotypic changes observed in K562 cells, Sox6 overexpression in human primary erythroid cultures is accompanied by an accelerated kinetics of maturation and an increased number of cells that achieve enucleation.
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From Searching for direct Sox6 targets, we found an evolutionarily conserved potential double Sox6 binding site lying 2.7kb 5' to the SOCS3 (Suppressor of Cytokine Signalling-3) transcription start site. This element is bound by Sox6 in vitro and in vivo and is activated by Sox6 in cotransfection experiments in K562 cells. SOCS3 is a negative regulator of the cellular response to several cytokines and plays a crucial role in regulating the balance between proliferation and differentiation in different cell types. 20 When SOCS3 is overexpressed in K562 and in primary cultures, cells stop growing with a kinetics similar to that observed upon Sox6 overexpression, suggesting that SOCS3 is indeed a relevant Sox6 target controlling cell proliferation.
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MATERIALS & METHODS

Plasmids preparation
The Sox6 murine cDNA was kindly provided by Prof. Michiko Hamada-Kanazawa, Kobe-Gakuin University, Japan. The Sox6 cDNA was transferred into the pCMV-Tag 4B plasmid (Stratagene, La Jolla, CA), in frame with a 3' FLAG epitope, (EcoRI-EcoRV sites), to produce the Sox6FLAG expression vector used in transfection assays. The Sox6 recombinant protein lacks the 49 C-ter aminoacids: this shorter molecule fully retains Sox6 biological properties. 6 The Sox6FLAG cassette (EcoRI-KpnI blunted sites) was then cloned immediately upstream to the IRES-Emerald GFP cassette (blunted BamHI site) of the pHR-SIN-BX-IR/EMW (derived from pHR-SIN-CSGW lentiviral vector 21 ). The TWEEN vector containing human SOCS3 cDNA was kindly provided by Dr. M.G. Francipane. 22 For transfections, the human SOCS3 promoter region (nt-393+12) was amplified from genomic DNA with Phusion DNA Polymerase (Finnzymes, Finland), and cloned into the pGL2 reporter vector (Promega, Fitchburg, WI).
The 70nt SOCS3 region (nt -2727-2678) containing the double Sox6 binding site (wild type or mutated), was cloned (SacI-NheI sites) upstream to the SOCS3 promoter. Amplified DNAs were sequenced to avoid undesired mutations. All primers are listed in the supplemental material section.
Lentiviral vector production
Viral stocks pseudotyped with the VSV-G envelope were produced by transient cotransfection of 4 plasmids in 293T cells. 23 Cells supernatant was collected, ultracentrifugated at 50,000xg for 2h at RT and the pellet was resuspended in PBS 1% and stored at -80°C. Viral titers were determined by transduction of HEL cells with serial dilutions of the vector stocks and by scoring GFP transgene expression by FACS analysis.
Cell cultures and transduction
K562 and HEL cells were cultured in RPMI medium supplemented by 10% Fetal Bovine Serum, PenStrep and L-glutamine. Transduction was performed overnight, with a Multiplicity Of Infection (MOI) of 30. CD34 + cells were purified from cord blood by positive selection from mononuclear cells 24 , using anti-CD34 microbeads (Miltenyi Biotech, Bergisch-Gladbach, Germany) according to the manufacturer's instructions. CD34 + cells (0.5-1x10 6 cells/ml) were prestimulated for 30 hours in CellGro medium (Cell Genix, Freiburg, Germany) supplemented with 300 ng/ml human stem cell factor (hSCF), 300 ng/ml human Flt-3-ligand (hFlt3-l), 100 ng/ml human thrombopoietin (TPO)
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From and 60 ng/ml human IL-3 (all PeproTech, Rocky Hill, NJ) on plates coated with retronectin (Takara Shuzo, Shiga, Japan). Transduction was performed overnight, with a MOI of 100. Erythroblasts (d6) derived from cord blood CD34 + cells were transduced overnight at MOI 50. The following day cells were washed and grown in suspension as erythroid culture. CD34 + cells were cultured for 2 weeks in StemSpan (Stem Cell Technologies, Vancouver, Canada) containing 20% of fetal bovine serum (FBS, Hyclone, Logan, UT) and supplemented with hSCF (10 ng/ml), human erythropoietin (EPO, 1 U/ml), hIL-3 (1 ng/ml), 10 -6 M dexamethasone (Sigma Aldrich, St Louis, MO), and 10 -6 M β-estradiol (Sigma), according to a single phase protocol, as modified from ref 24. CD34 + cells were seeded at a concentration of 10 5 cells/ml and diluted over time to maintain the concentration at 1-2 x 10 6 cells/ml. Erythroid differentiation was evaluated by staining with PE-conjugated anti-CD235 (GlycophorinA, GpA) (Dako, Carpinteria, CA) and FACS analysis. Morphological analysis and differential counting was performed on cytospins by MayGrünwald-Giemsa staining and microscope inspection.
CFU assay for human progenitors
CD34 + cells were plated at a density of 1000 cells/ml in methylcellulose medium containing hSCF, hGM-CSF, hIL3 and hEPO (GFH4434 Stem Cell Technologies, Vancouver, Canada). After 2 weeks, BFU-E, CFU-GM, and CFU-GEMM colonies were counted, and single colonies (20-30 for each experiment) were isolated for DNA and RNA extraction.
Chromatin Immunoprecipitation (ChIP) assay 1x10 6 K562 or 1x 10 7 primary cells for each Immunoprecipitation reaction were fixed with 0.4% formaldehyde for 10 minutes at room temperature, and chromatin was sonicated to a size of about 500 bp. Immunoprecipitation was performed after overnight incubation with anti-FLAG (Sigma, F-7425) or with the anti-Sox6 antibodies (Millipore Ab5805), and subsequent incubation with protein A agarose (Upstate). Immunoprecipitated DNA was then analysed by amplifying an equivalent of DNA from 10 4 K562 cells or 10 5 primary erythroblasts. Primers are listed in Supplemental materials.
RNA isolation and RT-PCR
Total RNA from 1x10 5 erythroid cells was purified with TRI-Reagent (Applied Biosystems, Foster City,CA), treated with RQ1 DNase (Promega) for 30 min at 37°C and retrotranscribed. Real time analysis was performed using ABI Prism 7500 (Applied Biosystems). Primers were designed to 
Western blot
Total and nuclear extracts from K562 cells were prepared according to standard protocols 25 and proteins were subjected to SDS-PAGE separation and blotting. The Sox6FLAG protein was detected by using the anti-FLAG antibody (Sigma F7425). Protein loading was checked by reprobing filters with an anti beta-actin antibody (Sigma). Antibodies binding was detected by using appropriate HRP-conjugated IgG and revealed by ECL (LiteAblot, Euroclone).
Transfection experiments
1,5 x 10 5 exponentially growing K562 cells were transfected in 0,5 ml of Opti-MEM medium (Invitrogen), using 2μl of Lipofectamine 2000 (Invitrogen), 800 ng of the reporter plasmid, and increasing amounts (from 0,2 to 1 μg) of the Sox6 expression plasmid (pCMV-Sox6Tag4B), per well. The pCMV-Tag4B empty vector was added to each transfection to equalize the total amount of DNA transfected in each reaction. After 24h, total cellular extracts were prepared and Luciferase activity was measured according to the Promega Luciferase reporter system protocol. Transfections were repeated in triplicate with three independent plasmid preparations. 32 P-labeled DNA probes were incubated with 5-10 μ g of total or nuclear extracts, for 20 min at 15°C in a buffer containing 5% glycerol, 50 mM NaCl, 20 mM Tris, pH 7.9, 0.5 mM EDTA, 5 mM MgCl, 1 mM dithiothreitol, 100 ng/μl poly(dG-dC), and 50 ng/μl bovine serum albumin in a 15-μl final volume. The reaction mixture was loaded onto a 8% polyacrylamide gel (29:1 acrylamidebisacrylamide ratio) and run at 4°C at 150V for 3h. Nuclear extracts were prepared according to standard protocols. 25, 26 The antibodies used were: anti-FLAG, (Sigma F7425); anti-GATA1 (SantaCruz N6, sc-265).
Electrophoretic mobility shift assay (EMSA)
Flow cytometric analysis and FACS
PE-conjugated anti-pSTAT5 (pY694) (BD, San Jose, CA) was used at 5 µg/mL. Intracellular staining was done according to the manufacturer's instructions, using BD™ Phosflow Fix Buffer I.
Propidium Iodide and AnnexinV staining were done using Annexin V Apoptosis Detection Kit
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K562 electroporated with pTween SOCS3-IRES-GFP expressing plasmid were FACS sorted for GFP expression 48 hours after transfection on a MoFlo (DAKO-Cytomation) cell sorter and the purity obtained was >95%.
Hemoglobin quantitation
Total Hemoglobin was quantitated by using the Human Hemoglobin-ELISA Quantitation Set (E80-135, Bethyl Laboratories Inc.), according to the Manifacturer's instructions. Hemin induction was obtained by growing K562 cells in the presence of 50 μM Hemin for four days.
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RESULTS
Sox6 overexpression strongly induces erythroid differentiation in K562 cells
To get insight into the role of Sox6 in human erythropoiesis, we first overexpressed Sox6 by lentiviral transduction of the human erythroleukemic cell line K562.
K562 cells were transduced with a vector containing a Sox6cDNA-FLAG expression cassette upstream to an IRES-GFP element (Sox6-GFP), and in parallel with a control Empty Vector (EV-GFP) ( Figure 1A ). The efficiency of transduction, assayed by monitoring GFP expression, was similar for both vectors (between 80 and 90%, data not shown). The expression of the exogenous Sox6 was verified by RT-PCR and by Western blot ( Figure 1B Moreover, FACS analysis shows a significant accumulation of a highly CD235 + (GlycophorinA) cell population (R6 in figure 1E ) in Sox6-K562 cells and, as expected, the expression of "erythroid genes" encoding for globins and key enzymes of the heme biosynthetic pathway (ALAS-E, FECH) is greatly increased (RealTime PCR, Supplementary Figure 2 ). mRNA from genes encoding the major "erythroid" transcription factors -GATA1, GATA2, EKLF, and p45-NFE2-do not change, suggesting that the observed phenotype is not mediated by a Sox6 effect on these transcription factors expression (not shown).
Since Sox6 has been proposed to repress the ε and γ embryonic globin genes 11, [13] [14] [15] , we carefully analyzed by Real Time PCR the relative changes in globin genes transcription upon Sox6 overexpression, taking GAPDH as an internal standard. Both β-like globin genes (ε and γ) and αlike genes (ζ and α), normally expressed by K562 cells, are -in terms of absolute amount of transcript-substantially induced by Sox6 overexpression; however, the ratio changes between the different β-like and α globin mRNAs chains suggest that Sox6 has a repressive effect on both γ and, even more evident, on ε gene, in agreement with literature data. ChIP demonstrates that Sox6 is indeed able to bind to the human ε and γ-globin gene promoters ( Supplementary Fig. 2 ).
The enhanced erythroid differentiation of Sox6-K562 cells is accompanied by a marked reduction of proliferation, with complete exhaustion of the culture within day 9 after transduction ( Figure 1F ).
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From FACS analysis shows, 72h after transduction, an increased number of AnnexinV positive cells (21.61% in Sox6-K562 vs. 13.93% in EV-K562), accompanied by an increased Propidium Iodide uptake (40.1% vs. 14.21%), suggesting increased apoptosis ( Figure 1H ). Real Time PCR analysis reveals decreased expression of the antiapoptotic genes Bcl-2 and, to a lesser extent, Bcl-xL ( Figure   1G ). Together these data suggest that Sox6 overexpression induces strong erythroid differentiation in K562 cells, accompanied by a dramatic reduction of cell proliferation.
Sox6 overexpression enhances and anticipates erythroid terminal differentiation of CD34 + derived primary erythroid cultures
Because of the profound effect of Sox6 overexpression on K562 cells, we moved to an ex vivo model of human erythroid cells differentiation, starting from cord-blood derived CD34 + cells. In this culture, erythroid progenitors first expand to the erythroblast stage (d0-d8) and then undergo terminal differentiation (d9-d14). Real time PCR analysis shows that Sox6 expression is absent in the most immature progenitors (d0 to d6), starts to be detectable at the beginning of the erythroblast differentiation phase (d8, corresponding to about 40% of GpA + cells), reaches a peak around d12 (about 80% of GpA + cells), and finally declines at the end of the culture (d14, >80% of GpA + cells) ( Figure 2A ). We therefore transduced the culture at d6, immediately prior to the onset of the endogenous Sox6 expression and we subsequently carried out the analysis on samples taken at d8, d10, d12 and d14. The percentage of GFP + cells evaluated by FACS demonstrates similar transduction efficiencies with EV-GFP and Sox6-GFP vectors (about 85%). The result of a representative experiment (out of three) is shown below.
Erythroid maturation was evaluated by measuring the proportion of GFP + GpA + cells by FACS . In control EV-erythroblasts, GFP + GpA + cells are about 70% at d10 and remain essentially stable until d14 ( Figure 2B , upper panels). By contrast, Sox6-erythroblasts reach the peak of GFP + GpA + double positivity at d10 (74,6%) and then decline to 56.1% at d12 and to 40.6% at d14, suggesting a progressive loss of transduced cells ( Figure 2B , lower panels).
Cells from the same samples as above were cytospun, stained with May-Grunwald/Giemsa and differentially counted to score the relative number of cells at the different stages of erythroid maturation ( Figure 2C The analysis of the expression of globin genes (α, ε, γ, β) demonstrates that Sox6 transduction greatly stimulates α, β and γ, but not ε expression, likely reflecting the accelerated cell maturation (Supplemental figure 3A) . Interestingly, in these cells, the ε/α and γ/α ratios are decreased (Supplemental figure 3B) , as in K562 cells, supporting the notion that, beside the general induction of maturation, Sox6 specifically concurs to inhibit ε and γ genes transcription.
Sox6 induces early loss of CD34 + progenitor cells
In a second set of experiments we directly transduced CD34 + cells with either the control or the Sox6 vector as above, and then an aliquot of transduced cells was either placed in the unilineage erythroid culture or plated in methylcellulose medium for colony forming unit (CFU) assay (exp. n =3). The proportion of GFP + cells in the Sox6 transduced culture progressively declines from about 30% at d4 to 3% by d14 ( Figure 3B ). This is in strong contrast with the high level of GFP + cells (80-90%) transduced with the control vector, which remains constant during erythroid maturation (d14). The low proportion of GFP-positive cells after Sox6 transduction suggests an early loss of Sox6-overexpressing cells, in agreement with the slow proliferation of these cells in the first 24h after transduction ( Figure 3A ). Of interest, the proportion of Sox6-transduced cells that are GPA + is already very high (34%, red) at d4, in contrast to the very low GPA-positivity (3,7%) of EVtransduced cells, suggesting that cells surviving Sox6 overexpression undergo accelerated erythroid differentiation ( Figure 3B ). Finally, the same transduced cells, seeded in methylcellulose, gave no GFP + colonies at d14, (FACS and RT-PCR analyses), indicating the loss of Sox6-transduced progenitors and/or of their progeny.
SOCS3 is an early Sox6 target gene
We then searched for direct Sox6 targets possibly responsible for the Sox6-induced erythroid differentiation. To this aim we performed a genome-wide search for evolutionarily conserved potential Sox6 binding sites by using the TFBScluster software 27 , taking the ε-globin Sox6 binding site as a model. 28 The in silico-identified candidate targets (more than 800), were filtered by selecting genes whose expression is known to be enriched in erythroid cells, on the basis of literature and of DNA microarray data comparing the expression profile of three distinct cells populations, FACS sorted from E11.5-E13.5 mouse fetal liver: pluripotent hematopoietic progenitors cKit + /TER119 -; erythroid-committed early progenitors cKit + /TER119 + ; more differentiated erythroblasts cKit -/TER119 ++ cells (ref. 28 and unpublished results). Among the remaining genes 28 , we focused on a double Sox6 consensus sequence lying 2700nt upstream to the Suppressor of Cytokine Signalling 3 (SOCS3) gene transcription start site ( Figure 4A ). SOCS3 is involved in the negative regulation of cytokines signalling, including Epo 29, 30 and IGF-1 31, 32 , both of which regulate erythroid growth. 33, 34 To functionally validate the Sox6 site found upstream to the SOCS3 gene, we set up EMSA experiments using as a probe an oligonucleotide containing either the wt double Sox6 consensus sequence (wt) or a mutated version (mut) ( Figure 4B ). Nuclear extracts from Sox6-K562 and EV-K562 were used.
Sox6 binds to its consensus sequence in a specific manner ( Figure 4B ). The band generated by the We then cloned a region of 70nt surrounding the Sox6 binding sites (either wt or mutated within the Sox consensus -same mutation proved to abolish Sox6 binding in EMSA-), upstream to the SOCS3 promoter 35 in a luciferase reporter plasmid, that we co-transfected in K562 cells together with a Sox6-expressing plasmid. While the wt SOCS3 element is activated by Sox6, the mutated element is insensitive to Sox6 co-transfection ( Figure 4D ).
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In untransduced CD34 + derived erythroid cultures, the profile of expression of SOCS3 shows a progressive increase in the last days of the culture (from day10, where its expression is at minimum, to day14) ( Figure 4F ). To correlate this pattern with the binding of Sox6 to the SOCS3 enhancer in vivo, we performed ChIP on chromatins from primary cells at day 9 and 12. As shown in Figure 5G lower panel, whereas at d9 no significant enrichment is observed, at d12 (corresponding to the peak of Sox6 expression, upper panel) the anti-Sox6 antibody does immunoprecipitate the SOCS3 enhancer, suggesting that this element is recognized in vivo by Sox6 when Sox6 accumulates at late stages of erythoid differentiation. In agreement with this, when Sox6 is overexpressed in CD34 +derived erythroblasts at d6 it induces SOCS3 mRNA overexpression (Real Time PCR at d8 and d10, Figure 4E , right panel).
These data confirm the ability of Sox6 to bind in vitro and in vivo to the SOCS3 conserved element and to transactivate it in a dose dependent manner in transfection experiments, confirming that SOCS3 is a direct Sox6 target.
SOCS3 overexpression mediates growth arrest
To evaluate to what extent the Sox6-dependent SOCS3 induction recapitulates the phenotype induced by Sox6 overexpression, we transduced CD34 + -derived erythroblasts (at day6, as for Sox6) with a SOCS3-IRES-GFP vector. SOCS3 overexpression strongly decreases cell proliferation ( Figure 5A ) but, in contrast to Sox6, does not affect erythroid maturation: differential cells counts at day 10 show that whereas Sox6-transduced cultures have an increased number of more mature cells at the expense of more immature populations, in SOCS3 transduced cultures the distribution of mature versus immature cells is similar to that of the control culture ( Figure 5B ). The Bcl-2 mRNA level is decreased in both Sox6-and SOCS3-overexpressing erythroblasts, further confirming the ability of SOCS3 (either induced by Sox6 or directly overexpressed) to induce a proapoptotic phenotype. Bcl-xL, which is known to increase in late erythroid differentiation, is downregulated upon SOCS3 overexpression, but slightly stimulated upon Sox6 transduction ( Figure 5C ). Figure 4 ) confirms that SOCS3 is indeed able to inhibit cell growth with a kinetics similar to that observed upon Sox6 overexpression but does not induce erythroid genes upregulation. This reinforces the notion that Sox6-induced SOCS3 activation is responsible for the reduced cell growth, but not for erythroid differentiation and that additional Sox6 targets are required to fully recapitulate the Sox6-induced phenotype. To verify our prediction we took advantage of the HEL cell line. These cells carry the myeloproliferative disorder-associated JAK2V617F mutation, which makes them insensitive to SOCS3. 36 Sox6 overexpression in these cells (at a level comparable to that obtained in K562 and primary cells, Supplemental Figure1A) does not decrease cell growth ( Figure 5D ) but significantly increases erythoid specific gene expression, as demonstrated by Real Time PCR of some prototypical erythroid genes ( Figure 5F ). Complemental to this data, SOCS3 overexpression in HEL cells neither induces a block in cell proliferation, as expected due to the JAK2V617F mutation, nor erythroid specific gene expression ( Figure 5D-F and differentiation of committed erythroid progenitor cells. 37, 38 To get insight into the pathways perturbed by the Sox6-dependent SOCS3 activation, we explored the effects of Sox6 overexpression on the aforementioned pathways in K562 cells, which are known to depend for their proliferation on autocrine IGF-1 signalling induced by Bcr/Abl. 39 
In addition, SOCS3 overexpression in K562 (Supplemental
Whereas the EPO/JAK/STAT pathway is not altered by Sox6 overexpression (Supplementary
DISCUSSION
Sox6 is emerging as an important gene controlling different steps of erythropoiesis, ranging from cell differentiation to the control of globin genes expression. 11, 13, 15, 40, 41 To get insight into its role in human erythroid cells we overexpressed Sox6 in the erythroleukemic cell line K562 and in primary erythroid cultures derived from cord blood purified CD34 + cells. In both cell types, Sox6-enforced expression drives significant erythroid terminal maturation.
K562 cells overexpressing Sox6 stop growing within 72h after transduction and undergo terminal erythroid differentiation, as shown by a strong induction of several erythroid specific genes, including heme-synthesis enzymes and globin chains. Of note, K562 cells differentiate only upon induction with high concentration of chemical inducers, such as hemin. 42 We obtained similar results in ex vivo erythroid cultures from CD34 + human Cord Blood cells ( Figure 2 ). In these cultures, the early peak of lentiviral-mediated Sox6 expression, causes a strong acceleration of differentiation, leading to the appearance at day 10 of culture of enucleated cells, absent in the control culture. This result confirms that Sox6 accelerates and boosts erythroid terminal differentiation of human progenitors.
Sox6 was recently reported to repress embryonic globin genes, possibly in cooperation with BCL11A 13, 15 and its level of expression has been proposed to play a role in HbF repression in human erythroid progenitors. 40 In these cells, knockdown of Sox6 leads to a modest induction of HbF, which is greatly increased by the combined knockdown of BCL11A, suggesting that although these two proteins cooperate to silence γ genes, BCL11A has a preeminent role. 15 We show that Sox6 strongly stimulates the transcription -in absolute terms-of all globin genes normally expressed by K562 cells, including γ and ε-globin ( Supplementary Figure 2) . This result might at first sight appear in conflict with the above reports. However, we suggest that Sox6 overexpression has two independent effects on globin synthesis: on one hand, by inducing cell differentiation, it increases the overall expression of globins genes in general; on the other hand, it negatively modulates ε and γ-globin transcription, relatively to other globin genes. In fact, the ε/α and γ/α ratios are reduced by 10 and 5 fold respectively in Sox6-K562 when compared with EV-K562. This is supported by the observation that both promoters are occupied by Sox6 in ChIP experiments (Supplementary figure   2 ). The detailed molecular mechanism of Sox6 action remains to be elucidated in terms of identification of targets and interactors: Sox6 acts either as activator and repressor of transcription, exerting an architectural role on chromatin organization 3 and further studies are required to better study these aspects of Sox6 activity.
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We demonstrate that SOCS3 is an early direct Sox6 target and that SOCS3 overexpression partially recapitulates the Sox6 effect of cell growth arrest in primary cells and in K562, whereas it does not affect proliferation in HEL cells that are insensitive to SOCS3 47 ( Figure 5 and Supplemental Figure   4 ).
Interestingly, in primary cells, while Sox6 overexpression is associated only with a decrease of Bcl-2 (Bcl-xL expression being increased, Figure 5B SOCS3 is involved in the downregulation of different signaling pathways, and its deregulation in hematopoiesis has been implicated in the pathogenesis of myeloproliferative disorders. 38, [45] [46] [47] Among pathways controlled by SOCS3, there are those involving EPO/JAK2/STAT5 and IGF-1/IGF-1R, both of which are required for erythroid progenitor cells survival. 37, 48 Our experiments in K562 show that the effects of Sox6 on proliferation are not mediated by alteration of the EPO/JAK2/STAT5 pathway (Supplemental Figure 5 ). However, in K562 cells, where Bcr/Abl promotes autocrine IGF-1 signalling thus stimulating cell proliferation and protecting cells from apoptosis 39 , IGF-1 mRNA is reduced when Sox6 or SOCS3 are overexpressed ( Figure 6 ). This suggests that reduction of IGF-1 levels, together with SOCS3-dependent signalling inhibition, might contribute to the decreased cell proliferation downstream to Sox6 (and SOCS3).
Since autocrine or paracrine IGF-1 signalling is required in many stages of hematopoiesis and its inappropriate activation is an important event in leukemia 38, 39 , the SOCS3 activation elicited by figure. (B) Diagram showing the known relationships (references are indicated above the connecting lines) between the genes/pathways studied in this paper: SOCS3 interferes with EPO/JAK/STAT pathway by binding EPOR and JAK 37 , and with IGF-1 signalling by binding IGF-1R. 48 K562 proliferation is sustained by an autocrine IGF-1 signalling loop activated by Bcr/Abl. 39 Here we propose that the SOCS3-mediated inhibition of IGF-1 transcription might be responsible for K562 decreased proliferation and increased apoptosis downstream to Sox6 (continuous line). We can not exclude that Sox6 could also act on IGF-1 through other -still unknown-pathways (dashed line).
